基础医学与临床 ›› 2018, Vol. 38 ›› Issue (4): 578-582.
• 短篇综述 • 上一篇 下一篇
熊伟鹏
收稿日期:
修回日期:
出版日期:
发布日期:
通讯作者:
Weipeng Xiong
Received:
Revised:
Online:
Published:
Contact:
摘要： 肿瘤免疫疗法研究在肿瘤治疗领域取得了突破性的进展。程序性死亡受体1（PD-1）主要表达于T淋巴细胞表面，是一种重要的免疫调节蛋白。PD-1及其配体PD-L1相互作用参与肿瘤诱导的免疫抑制效应。针对PD-1/PD-L1信号通路的抗体药物在临床应用中呈现出显著性的疗效。
关键词: 肿瘤，免疫疗法，程序性死亡受体1，抗体药物
Abstract: Research in immunotherapy has achieved important progress in tumor treatments. Programmed cell death receptor 1 (PD-1) is mainly expressed on the T lymphocyte surface and serves as an important immune regulator. The interactions of PD-1 and its ligand, PD-L1, involve in tumor-induced immunosuppression. Some of the approved antibody drugs targeting PD-1/PD-L1 signaling showed significant clinical benefits.
Key words: tumor, immunotherapy, programmed cell death receptor 1, antibody drug
熊伟鹏. 细胞程序性死亡受体1信号通路在肿瘤免疫疗法中的应用[J]. 基础医学与临床, 2018, 38(4): 578-582.
Weipeng Xiong. Role of programmed cell death receptor 1 signaling pathway in cancer immunotherapy[J]. Basic & Clinical Medicine, 2018, 38(4): 578-582.
/ 推荐
导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks
链接本文: https://journal11.magtechjournal.com/Jwk_jcyxylc/CN/
https://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2018/V38/I4/578
